Profusa (NASDAQ:PFSA – Get Free Report) and Check-Cap (NASDAQ:MBAI – Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability and valuation.
Risk and Volatility
Profusa has a beta of 0.35, suggesting that its share price is 65% less volatile than the S&P 500. Comparatively, Check-Cap has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.
Profitability
This table compares Profusa and Check-Cap’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profusa | N/A | N/A | -1,348.07% |
| Check-Cap | N/A | N/A | N/A |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profusa | 1 | 0 | 0 | 0 | 1.00 |
| Check-Cap | 1 | 0 | 0 | 0 | 1.00 |
Valuation and Earnings
This table compares Profusa and Check-Cap”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profusa | $100,000.00 | 12.50 | -$35.82 million | ($169.72) | 0.00 |
| Check-Cap | N/A | N/A | $4.14 million | ($2.77) | -0.50 |
Check-Cap has lower revenue, but higher earnings than Profusa. Check-Cap is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
9.8% of Profusa shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 0.8% of Profusa shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
About Profusa
NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.
About Check-Cap
Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient’s back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.
Receive News & Ratings for Profusa Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profusa and related companies with MarketBeat.com's FREE daily email newsletter.
